Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI325 Monotherapy and Plus Sintilimab in Advanced Solid Tumors
NCT05119998Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2022
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ibi325 in solid tumor (2 arms), sponsored by Innovent Biologics. Primary endpoints: Number of patients with Dose-Limiting Toxicity and Number of patients with treatment related Adverse Events. Started Feb 2022; status: completed.
02
Drugs
ibi325
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05119998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119998.